RxDoctor Payments Data

Pamela Orellana Chasi, MD

Family Medicine · Weehawken, NJNPI 1699157446

Payments from drug & device makers

$763in general payments, 2019–2025

Across 30 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$253
  • AstraZeneca$207
  • Exact Sciences$142
  • Lilly USA, LLC$77
  • Novartis$37
  • GSK$31
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$74798%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk9$253
AstraZeneca6$207
Exact Sciences6$142
Lilly USA, LLC4$77
Novartis2$37
GSK2$31
Globus Medical1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$763 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$36,112
Medicare patients
90
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$91,572
FarxigaDapagliflozin Propanediol47$43,501
LinzessLinaclotide38$29,403
VascepaIcosapent Ethyl46$27,602
JardianceEmpagliflozin22$23,007
JanuviaSitagliptin Phosphate11$16,421
Diclofenac Sodium69$4,679
Atorvastatin Calcium240$2,945
Rosuvastatin Calcium116$1,948
Albuterol Sulfate HfaAlbuterol Sulfate73$1,590
Lidocaine18$1,388
Omeprazole57$1,214
Amlodipine Besylate116$846
Levothyroxine Sodium86$828
Ventolin HfaAlbuterol Sulfate15$799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$253$91,57288 claims
AstraZenecaFarxiga$207$43,50147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Weehawken

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →